Dosimetric Considerations in Radioimmunotherapy and Systemic Radionuclide Therapies: a Review

Overview

Journal World J Nucl Med

Publisher Thieme

Specialty Nuclear Medicine

Date 2011 Dec 7

PMID 22144871

Citations 20

Authors

Kelvin S H Loke

Ajit K Padhy

David C E Ng

Anthony S W Goh

Chaitanya Divgi

Affiliations

Soon will be listed here.

Abstract

Radiopharmaceutical therapy, once touted as the "magic bullet" in radiation oncology, is increasingly being used in the treatment of a variety of malignancies; albeit in later disease stages. With ever-increasing public and medical awareness of radiation effects, radiation dosimetry is becoming more important. Dosimetry allows administration of the maximum tolerated radiation dose to the tumor/organ to be treated but limiting radiation to critical organs. Traditional tumor dosimetry involved acquiring pretherapy planar scans and plasma estimates with a diagnostic dose of intended radiopharmaceuticals. New advancements in single photon emission computed tomography and positron emission tomography systems allow semi-quantitative measurements of radiation dosimetry thus allowing treatments tailored to each individual patient.

Citing Articles

The application of radionuclide therapy for breast cancer.

Musket A, Davern S, Elam B, Musich P, Moorman J, Jiang Y Front Nucl Med. 2024; 3:1323514.

PMID: 39355029 PMC: 11440853. DOI: 10.3389/fnume.2023.1323514.

Non-Invasive Imaging Biomarkers to Predict the Hepatopulmonary Shunt Fraction Before Transarterial Radioembolization in Patients with Hepatocellular Carcinoma.

Hamm C, Busch F, Pohlmann A, Shewarega A, He Y, Schmidt R J Hepatocell Carcinoma. 2023; 10:27-42.

PMID: 36660411 PMC: 9842483. DOI: 10.2147/JHC.S391537.

Combination of [Lu]Lu-DOTA-TATE Targeted Radionuclide Therapy and Photothermal Therapy as a Promising Approach for Cancer Treatment: In Vivo Studies in a Human Xenograft Mouse Model.

Simon M, Jorgensen J, Khare H, Christensen C, Nielsen C, Kjaer A Pharmaceutics. 2022; 14(6).

PMID: 35745856 PMC: 9227845. DOI: 10.3390/pharmaceutics14061284.

Evaluation of Safety and Dosimetry of Lu-DOTA-ZOL for Therapy of Bone Metastases.

Fernandez R, Eppard E, Lehnert W, Jimenez-Franco L, Soza-Ried C, Ceballos M J Nucl Med. 2021; 62(8):1126-1132.

PMID: 33419945 PMC: 8833870. DOI: 10.2967/jnumed.120.255851.

Quantitative PET in the 2020s: a roadmap.

Meikle S, Sossi V, Roncali E, Cherry S, Banati R, Mankoff D Phys Med Biol. 2020; 66(6):06RM01.

PMID: 33339012 PMC: 9358699. DOI: 10.1088/1361-6560/abd4f7.

References

Barendswaard E, Humm J, ODonoghue J, Sgouros G, Finn R, Scott A . Relative therapeutic efficacy of (125)I- and (131)I-labeled monoclonal antibody A33 in a human colon cancer xenograft. J Nucl Med. 2001; 42(8):1251-6. View

Fox R, Klemp P, Egan G, Mina L, Burton M, Gray B . Dose distribution following selective internal radiation therapy. Int J Radiat Oncol Biol Phys. 1991; 21(2):463-7. DOI: 10.1016/0360-3016(91)90797-8. View

Sgouros G, Kolbert K, Sheikh A, Pentlow K, Mun E, Barth A . Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med. 2004; 45(8):1366-72. View

Wahl R, Zasadny K, MacFarlane D, Francis I, Ross C, Estes J . Iodine-131 anti-B1 antibody for B-cell lymphoma: an update on the Michigan Phase I experience. J Nucl Med. 1998; 39(8 Suppl):21S-27S. View

Yeh S, Larson S, Burch L, Kushner B, LaQuaglia M, Finn R . Radioimmunodetection of neuroblastoma with iodine-131-3F8: correlation with biopsy, iodine-131-metaiodobenzylguanidine and standard diagnostic modalities. J Nucl Med. 1991; 32(5):769-76. View

Eary J, Collins C, Stabin M, Vernon C, Petersdorf S, Baker M . Samarium-153-EDTMP biodistribution and dosimetry estimation. J Nucl Med. 1993; 34(7):1031-6. View

Hamdy N, Papapoulos S . The palliative management of skeletal metastases in prostate cancer: use of bone-seeking radionuclides and bisphosphonates. Semin Nucl Med. 2001; 31(1):62-8. DOI: 10.1053/snuc.2001.18767. View

Helisch A, Forster G, Reber H, Buchholz H, Arnold R, Goke B . Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2004; 31(10):1386-92. DOI: 10.1007/s00259-004-1561-6. View

Bolch W, Bouchet L, ROBERTSON J, Wessels B, Siegel J, Howell R . MIRD pamphlet No. 17: the dosimetry of nonuniform activity distributions--radionuclide S values at the voxel level. Medical Internal Radiation Dose Committee. J Nucl Med. 1999; 40(1):11S-36S. View

10.

Smith-Jones P, Vallabhajosula S, Navarro V, Bastidas D, Goldsmith S, Bander N . Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor. J Nucl Med. 2003; 44(4):610-7. View

11.

Barendswaard E, Scott A, Divgi C, WILLIAMS Jr C, Coplan K, Riedel E . Rapid and specific targeting of monoclonal antibody A33 to a colon cancer xenograft in nude mice. Int J Oncol. 1998; 12(1):45-53. DOI: 10.3892/ijo.12.1.45. View

12.

Kaminski M, Tuck M, Estes J, Kolstad A, Ross C, Zasadny K . 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005; 352(5):441-9. DOI: 10.1056/NEJMoa041511. View

13.

Bouchet L, Bolch W, Blanco H, Wessels B, Siegel J, Rajon D . MIRD Pamphlet No 19: absorbed fractions and radionuclide S values for six age-dependent multiregion models of the kidney. J Nucl Med. 2003; 44(7):1113-47. View

14.

Oosterwijk E, Bander N, Divgi C, Welt S, Wakka J, Finn R . Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. J Clin Oncol. 1993; 11(4):738-50. DOI: 10.1200/JCO.1993.11.4.738. View

15.

Ho S, Lau W, Leung T, Chan M, Johnson P, Li A . Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer. Eur J Nucl Med. 1997; 24(3):293-8. DOI: 10.1007/BF01728766. View

16.

Wiseman G, White C, Stabin M, Dunn W, Erwin W, Dahlbom M . Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur J Nucl Med. 2000; 27(7):766-77. DOI: 10.1007/s002590000276. View

17.

de Jong M, Breeman W, Valkema R, Bernard B, Krenning E . Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. J Nucl Med. 2005; 46 Suppl 1:13S-7S. View

18.

Fietz T, Uharek L, Gentilini C, Muessig A, Rieger K, Marinets O . Allogeneic hematopoietic cell transplantation following conditioning with 90Y-ibritumomab-tiuxetan. Leuk Lymphoma. 2005; 47(1):59-63. DOI: 10.1080/10428190500260478. View

19.

Vallabhajosula S, Goldsmith S, Kostakoglu L, Milowsky M, Nanus D, Bander N . Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity. Clin Cancer Res. 2005; 11(19 Pt 2):7195s-7200s. DOI: 10.1158/1078-0432.CCR-1004-0023. View

20.

Stabin M . MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 1996; 37(3):538-46. View